MAYNE RECEIVES GENERIC APPROVALS IN THE U.S., UK

Mayne Pharma announced it has received approval from the FDA for its generic freeze-dried epirubicin. The company also announced that it has received marketing authorization for its oxaliplatin product from the UK's Medicines and Healthcare Products Regulatory Agency.

Epirubicin, a cancer drug sold by Pfizer under the brand name Ellence, generated sales of approximately $68 million in the U.S. market during the year ending in June, according to figures from IMS Health.

Oxaliplatin, a generic version sanofi-aventis' Eloxatin, is a cancer drug used in the treatment of Stage III and metastatic colorectal cancer. The drug generated sales of approximately $53 million in the UK market during the year ending in June, according to IMS Health. In May a ruling by the UK High Court found in favor of Mayne in regard to certain patents for its oxaliplatin products.